Down with the erythropoietin. Long live the erythropoietin!

Current Drug Targets

Volumn 10, Issue 10, 2009, Pages 1028-1032

  Buemi, Michele ^a   Lacquaniti, Antonio ^a   Bolignano, Davide ^a   Cernaro, Valeria ^a   Campo, Susanna ^a   Grasso, Giovanni ^a   Buemi, Antoine ^a   Donato, Valentina ^a   Sturiale, Alessio ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN;

ANEMIA; ANGIOGENESIS; ATHLETE; BLOOD TRANSFUSION; BLOOD VESSEL INJURY; BREAST CANCER; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); DOPING; ERYTHROCYTE COUNT; ERYTHROPOIESIS; HEART DISEASE; HEART PROTECTION; HUMAN; INHIBITION KINETICS; LIVER CELL CARCINOMA; LIVER RESECTION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; METASTASIS; METASTASIS POTENTIAL; MULTIPLE MYELOMA; MULTIPOTENT STEM CELL; NEUROBLASTOMA; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OVARY CANCER; PLEIOTROPY; PRESCRIPTION; REGENERATIVE MEDICINE; REVIEW; SALAMANDER; THROMBOSIS; TISSUE DIFFERENTIATION; TISSUE REGENERATION; TUMOR VASCULARIZATION; UTERUS CANCER;

ANEMIA; ANGIOGENESIS INDUCING AGENTS; ANIMALS; ATHLETIC PERFORMANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; REGENERATIVE MEDICINE; URODELA;

EID: 70450178530     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789577981     Document Type: Review

References (32)

1. Buemi M, Nostro L, Romeo A, Giacobbe MS, Aloisi C, Sturiale A, et al. From the oxygen to the organ protection: erythropoietin as protagonist in internal medicine. Cardiovasc Hematol Agents Med Chem 2006; 4: 299-311. (Pubitemid 44574841)
2. Marti HH, Gassmann M, Wenger RH, Kvietikova I, Morganti-Kossmann MC, Kossmann T, et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int 1997; 51: 416-418 (Pubitemid 27088152)
3. Choi K. Hemangioblast development and regulation. Biochem Cell Biol 1998; 76: 947-956
4. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999; 93: 2627-2636 (Pubitemid 29181195)
5. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, et al. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003; 62: 228-236 (Pubitemid 36330674)
6. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39-61.
7. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci USA 2008; 105: 6185-6190 (Pubitemid 351758420)
8. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 2004; 279: 20655-20662 (Pubitemid 38656460)
9. Aydin Z, Duijs J, Bajema IM, van Zonneveld AJ, Rabelink TJ. Erythropoietin, progenitors, and repair. Kidney Int Suppl 2007; 107: S16-20.
10. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006; 70: 246-250 (Pubitemid 44086573)
11. Madeddu P, Emanueli C. Switching on reparative angiogenesis: essential role of the vascular erythropoietin receptor. Circ Res 2007; 100: 662-669 (Pubitemid 46594872)
12. Sturiale A, Campo S, Crascì E, Aloisi C, Buemi M. Experimental models of acute renal failure and erythropoietin: what evidence of a direct effect? Ren Fail 2007; 29: 379-386
13. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alpha in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-5972 (Pubitemid 46300213)
14. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo controlled trial. Lancet 2004; 362: 1255-1260 (Pubitemid 37324251)
15. Henke M, Mattern D, Pepe M, Bézay C, Weissenberger C, Werner M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24: 4708-4713
16. Lai SY, Grandis JR. Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol 2006; 24: 4675-4676 (Pubitemid 46630930)
17. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107: 1892-1895 (Pubitemid 43289368)
18. Danish Head and Neck Cancer Group, Interim analysis of DAHANCA 10, 2006, 12, 1, Available at http://frejacms.au.dk/-dahanca/get-media-file. php?mediaid=125. Accessed May 12, 2007.
19. U.S. Food and Drug Administration, http://www.fda.gov/medwatch/safety/ 2007/safety07.htm# Aranesp. Accessed May 12, 2007.
20. Ribatti D, Marzullo A, Gentile A, Longo V, Nico B, Vacca A, et al. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 2007; 50: 591-596 (Pubitemid 46495824)
21. Ribatti D, Poliani PL, Longo V, Mangieri D, Nico B, Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology, 2007; 50: 636-641 (Pubitemid 46495823)
22. Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007; 2: e549. (Pubitemid 351193995)
23. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354: 2079-2080
24. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002; 23: 1797-1805 (Pubitemid 35355929)
25. Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001; 84: 836-843 (Pubitemid 32275660)
26. Escudier B, Cosaert J, Pisa P. Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Rev Anticancer Ther 2008; 8(10): 1545-1557
27. Sturiale A, Campo S, Crascì E, Coppolino G, Bolignano D, Grasso G, et al. Erythropoietin and its lost receptor. Nephrol Dial Transplant. 2007; 22:1484-1485
28. Sanchez Alvarado A. La règènèration tissutaireå. Biofutur 2000; 48: 213.
29. Yin VP, Poss KD. New regulators of vertebrate appendage regeneration. Curr Opin Genet Dev 2008; 18: 381-386
30. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008; 105: 10925-10930
31. Coleman TR, Westenfelder C, Tögel FE, Yang Y, Hu Z, Swenson L, et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.Proc Natl Acad Sci USA 2006; 103: 5965-5970
32. DeWitt N. Regenerative medicine. Nature 2008; 453: 301.